Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins

Blood

Volumn 95, Issue 12, 2000, Pages 3929-3938

  Konopleva, Marina ^a   Tari, Ana M ^a   Estrov, Zeev ^a   Harris, David ^a   Xie, Zhong ^a   Zhao, Shourong ^a   López Berestein, Gabriel ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTARABINE; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034660068     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3929     Document Type: Article

References (62)

1. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992;52:5407-5411.
2. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151-157.
3. Walton WI, Whysong D, O'Connor PM, Hockenberry D, Korsmeyer SJ, Kohn KW. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 1993;53:151-157.
4. Kamesaki S, Kamesaki H, Jorgensen TJ, et al. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 1993;53:4251-4256.
5. Tang C, Willingham MC, Reed JC, et al. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 1994;8:1960-1969.
6. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev. 1994; 4:71-79.
7. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 1994;84:595-600.
8. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 1995;55:735-738.
9. Teixeira C, Reed JC, Pratt MAC. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995;55:3902-3907.
10. Bradbury DA, Russell NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol. 1995;91:374-379.
11. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
12. Karakas T, Maurer U, Weidman E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9:159-165.
13. Maung ZT, MacLean FR, Reid MM, et al. The relationship between bcl-2 expression and response to chemotherpay in acute leukaemia. Br J Haematol. 1994;88:105-109.
14. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia. 1995;9:1191-1198.
15. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem. 1996;271:12,695-12,698.
16. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med. 1996;183:2219-2226.
17. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A. 1996;93:9545-9552.
18. Huang DCS, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 1997;16:4628-4638.
19. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996;274:1664-1667.
20. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 1995;17: 501-508.
21. Park J, Bernstein I, Hockenbery D. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood. 1995;86:868-876.
22. Andreeff M, Jiang S, Zhang X, et al. Expression of bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retionic acid. Leukemia 1999;13:1881-1892.
23. Hu Z, Minden M, McCulloch E. Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the ARA-C sensitivity of leukemic stem cells. Leukemia. 1995;9:1667-1673.
24. Hu ZB, Minden MD, McCulloch EA. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Blood. 1998;92:1768-1775.
25. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137-1141.
26. Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berenstein G. Liposomal delivery of oligonucleotides. Leuk Lymphoma. 1996;21:93-97.
27. Tari AM, Lopez-Berenstein G. Oligonucleotide therapy for hematological malignancies. J Liposomal Res. 1997;7:19-30.
28. Tari AM, Stephens C, Rosenblum M, Lopez-Berenstein G. Pharmacokinetics, tissue distribution, and safety of P-ethoxy oligonucleotides incorporated in liposomes. J Liposome Res. 1998;8:251-264.
29. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995;9:131-138.
30. Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 1994;9: 3049-3055.
31. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 onco-protein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994;5: 61-65.
32. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al Katib A. Antisense oligodeoxyribo-nucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther. 1995;2:207-212.
33. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91: 991-1000.
34. Pallis M., Zhu YM, Russell NH. Bcl-XL is heterogeneously expressed by acute myeloblastik: leukaemia cells and is associated with autonomous growth in vitro and with p-glycoprotein expression. Leukemia. 1997;11:945-949.
35. Deng G, Lane C, Kornblau S, et al. Ratio of bcl-xshort to bcl-xlong is different in good-and poor-prognosis subsets of acute myeloid leukemia. Mol. Med. 1998;4:158-164.
36. McGrath T, Center MS. Mechanisms of MDR in HL60 cells: evidence that a surface membrane protein distinct trom p-glycoprotein contributes to reduced cellular accumulation of drugs. Cancer Res. 1988;48:3959-3669.
37. Zhao S, Xie Z, Konopleva M, Reed JC, Andreeff M. Differential expression of Bcl-2 family proteins in doxorubicin-resistant and parental HL-60 cells. Blood. 1997;90(suppl 1): 2216.
38. Tari A, Tucker S, Deisseroth A, Lopez-Berestein GF. Liposomal delivery of Methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood. 1994;84:601-607.
39. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986;83:5214-5218.
40. Lisovsky M, Estrov Z, Zhang X, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996;88:3987-3997.
41. Schwartz A, Fernandez-Repollet E. Development of clinical standards for flow cytometry. Ann N Y Acad Sci. 1993;677:28-39.
42. Lavabre-Bertrand T, Janossy G, Ivory K, Peter R, Seeker-Walker L, Porwit-MacDonald A. Leukemia associated changes identified by quantitative flow cytometry: I. CD10 expression. Cytometry. 1994; 18:209-217.
43. Andreetf M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cylometric analysis of cellular DNA and RNA. Blood. 1980;55:282-293.
44. Buick RN, Till JE, McCulloch EA. A colony assay for proliferative blast cells circulating in myeloblastic leukemia. Lancet. 1977;1:862-863.
45. Estrov Z, Black RA, Sleath PR, et al. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood. 1995;86:4594-4602.
46. Freedman MH, Chan HS, Chang L. Childhood erythroleukemia: studies on pathogenesis using colony assays. Am J Pediatr Hematol Oncol. 1986;8:2-7.
47. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph notes. Am J Pathol. 1994; 145:515-525.
48. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res. 1994;54:5501-5507.
49. Krajewski S, Krajewska M, Reed JC. Immunohistochemical analysis of in vivo patterns of Bak expression, a pro-apoptotic member of bcl-2 family. Cancer Res. 1996;56:2849-2855.
50. Takayama S, Krajewski S, Krajewska M, et al. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res. 1998;58:3116-3131.
51. Dole M, Nunez G, Merchant AK, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994;54:3253-3259.
52. Bradbury D, Zhu YM, Russell N. Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia. 1994; 8:786-791.
53. Kornblau SM, Thall P, Estrov Z, et al. The prognostic impact on bcl2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999;5:1758-1766.
54. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998;92: 3090-3097.
55. Xie Z, Zhao S, Xu H, McQueen T, Andreeff M. Differential expression patterns in human myeloblastic leukemia HL-60 and multidrug resistant HL-60/Dox cells analyzed by human cDNA expression array [abstract]. Blood. 1998;92 (suppl 1):387a.
56. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. In press.
57. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. "Low-risk" myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075-1082.
58. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: a prognostic indicator strongly related p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994;86:499-504.
59. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 1994;145:1191-1198.
60. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993;329:690-694.
61. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995; 1:1103-1110.
62. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia. 1994;8:S33-S37.